GlassScriptPhysician profile
Erin Nest
NPI 1346676939
$4,358.30
in general payments reported to CMS, 2019-2025
36 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $771 · 2023: $793 · 2024: $1,161 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $737.55 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $702.39 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $567.50 | 2021-2025 | |
| Pfizer INC. | $437.29 | 2021-2025 | |
| Exact Sciences Corporation | $184.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $175.14 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $168.52 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $153.09 | 2022-2025 | |
| Axsome Therapeutics, INC. | $137.34 | 2025 | Auvelity, Symbravo |
| Astrazeneca Pharmaceuticals LP | $132.85 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.33 | 2021-2023 | Stiolto Respimat, Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $92.32 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.68 | 2024-2025 | Caplyta |
| Cranial Technologies, INC | $69.33 | 2023-2024 | Doc Band |
| Alk-Abello, INC | $55.28 | 2023-2024 | Grastek, Ragwitek, Odactra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $49.61 | 2023-2024 | Veozah |
| Abbott Laboratories | $48.59 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $42.00 | 2022-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $37.94 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $34.96 | 2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $34.75 | 2024-2025 | Opsumit, Uptravi |
| Tactile Systems Technology INC | $31.55 | 2023 | Flexitouch Plus, Entre Plus |
| Biohaven Pharmaceuticals, INC. | $30.85 | 2021 | |
| Merck Sharp & Dohme LLC | $25.02 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
| Kyowa Kirin, INC. | $22.62 | 2024 | Crysvita |
| Verrica Pharmaceuticals INC. | $20.75 | 2024 | Ycanth |
| Ironshore Pharmaceuticals INC. | $20.61 | 2023 | Jornay Pm |
| Averitas Pharma INC. | $19.64 | 2024 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $19.45 | 2022 | |
| Boston Scientific Corporation | $19.29 | 2025 | General - Pain Management |
| Seqirus USA INC | $18.19 | 2022 | |
| Vivus LLC | $17.27 | 2025 | Qsymia |
| Dynavax Technologies Corporation | $15.51 | 2023 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2021 | |
| Aimmune Therapeutics, INC. | $13.65 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $9.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Nest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.